Liminatus Pharma, Inc. Class A Common Stock (LIMN NASDAQ) stock market data APIs
$3.8661
-0.17(-4.4%)
as of October 7, 2026
Try our APIs with
free plan!
Liminatus Pharma, Inc. Class A Common Stock Financial Data Overview
Price chart is built with
Anychart
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Prev. Close
3.8661
Open
3.6978
High
3.9184
Low
3.6218
52 wk Range
3.29-141.5
Market Cap
5 212 K
Shares Outstanding
1 343 K
EPS
-0.03
Beta
0.754
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Liminatus Pharma, Inc. Class A Common Stock data using free add-ons & libraries
Get Liminatus Pharma, Inc. Class A Common Stock Fundamental Data
Liminatus Pharma, Inc. Class A Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA: -4 063 116
- Earnings Per Share: -24
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Liminatus Pharma, Inc. Class A Common Stock Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-14
- EPS/Forecast: NaN
Get Liminatus Pharma, Inc. Class A Common Stock End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Liminatus Pharma, Inc. Class A Common Stock News
New
Liminatus Pharma regains Nasdaq compliance
Liminatus Pharma (LIMN [https://seekingalpha.com/symbol/LIMN]) announced on Tuesday that the company has regained compliance with Nasdaq’s minimum bid price rule. As previously disclosed, on Januar...
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
Liminatus Pharma Inc. FULLERTON, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company") today announced that the Company has regained complian...
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
Liminatus Pharma Inc. FULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company") today announced that its board of directors has adopted...
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
Liminatus Pharma Inc. FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biopharmaceutical company developing novel therapies...
Get Liminatus Pharma, Inc. Class A Common Stock fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.